Like Lilly, Novo Nordisk is developing multiple other candidates, including the unimolecular GLP-1 and amylin receptor agonist amycretin and next-gen subcutaneous obesity treatment candidate, CagriSema. NVO is also evaluating several other obesity drugs across separate early to mid-stage studies.